Prevalence of antimicrobial drug use and concurrent bacterial infections in hospitalized COVID-19 patients.

Prevalence of antimicrobial drug use and concurrent bacterial infections in hospitalized COVID-19 patients. - Prevalence of antimicrobial drug use and concurrent bacterial infections in hospitalized COVID-19 patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045814

Enrollment

1000

Registered

2021-10-21

Start date

2021-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All consecutive symptomatic COVID-19 patients who are confirmed by SARS-CoV-2 nucleic acid or antigen tests and who are hospitalized in our hospital

Exclusion criteria

Exclusion criteria: Patients who are transferred to other hospitals for intensive care

Design outcomes

Primary

Measure	Time frame
1. Prevalence of antimicrobial drug use during hospitalization 2. Proportion of patients who had microbiologically confirmed concurrent infection during hospitalization	—

Countries

Japan

Contacts

Public ContactJunpei Komagamine

NHO Tochigi Medical Center Internal medicine

jkomagamine@tochigi-mc.jp028-622-5241

Outcome results